ARTICLE | Clinical News
GSK961081: Phase IIb started
January 10, 2011 8:00 AM UTC
GlaxoSmithKline began a double-blind, double-dummy, placebo-controlled, international Phase IIb trial in about 425 patients to evaluate once-daily 100, 400 or 800 µg doses or twice-daily 100, 200 or 4...